Covalon Technologies (CVE:COV) is hitting a new 52-week high at $3.31

Shares of Covalon Technologies Ltd. (CVE:COV – Get Your Free Report ) hit a new 52-week high on Tuesday . The company traded as high as $3.31 and last traded at $3.20, with a volume of 47076 shares traded. Shares previously closed at $3.17.

Covalon Technologies price performance

The firm has a market cap of $80.18 million, a P/E ratio of -81.00 and a beta of 0.64. The company has a current ratio of 5.24, a quick ratio of 6.45, and a debt-to-equity ratio of 4.98. The company has a 50 day moving average of $2.62 and a two hundred day moving average of $1.87.

Covalon Technologies (CVE:COV – Get Your Free Report ) last posted its quarterly earnings data on Wednesday, August 21st. The company reported $0.06 earnings per share for the quarter. The business had revenue of $9.22 million for the quarter. Covalon Technologies had a negative return on equity of 3.85% and a negative net margin of 2.82%. On average, sell-side analysts anticipate that Covalon Technologies Ltd. will post 0.3 earnings per share for the current fiscal year.

About Covalon Technologies

(Get a free report)

Covalon Technologies Ltd. is engaged in the research, development, manufacturing and commercialization of medical products in the infection management, advanced wound care and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America and internationally. The company’s technologies comprise the collagen matrix platform that is used to manufacture a family of products for the treatment of chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor sites and grafts, traumatic wounds that heal by secondary intention, wounds surgical lacerations, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for the family of pre- and post-surgical and vascular access products that are designed to kill bacteria or yeast that come into contact with the antimicrobial silicone, providing broad-spectrum antimicrobial activity.

Recommended articles

Get news and reviews for Covalon Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Covalon Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.